

BMJ Open

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email info.bmjopen@bmj.com

BMJ Open

Clinical prediction models to diagnose neonatal sepsis: a scoping review protocol

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2020-039712
Article Type:	Protocol
Date Submitted by the Author:	23-Apr-2020
Complete List of Authors:	<p>Neal, Samuel; University College London, UCL Great Ormond Street Institute of Child Health Musorowegomo, David; University of Zimbabwe College of Health Sciences, Department of Paediatrics and Child Health Gannon, Hannah; University College London, UCL Great Ormond Street Institute of Child Health Cortina Borja, Mario; University College London, UCL Great Ormond Street Institute of Child Health Heys, Michelle; University College London, UCL Great Ormond Street Institute of Child Health; East London NHS Foundation Trust, Specialist Children's and Young People's Services Chimhini, Gwen; University of Zimbabwe College of Health Sciences, Department of Paediatrics and Child Health Fitzgerald, Felicity; University College London, UCL Great Ormond Street Institute of Child Health</p>
Keywords:	NEONATOLOGY, INFECTIOUS DISEASES, STATISTICS & RESEARCH METHODS, Neonatal intensive & critical care < INTENSIVE & CRITICAL CARE, PAEDIATRICS

SCHOLARONE™
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

Clinical prediction models to diagnose neonatal sepsis: a scoping review protocol

Neal SR^{1*}, Musorowegomo D^{2*}, Gannon H¹, Cortina-Borja M¹, Heys M^{1,3}, Chimhini G^{2†}, Fitzgerald F^{1‡}

1. UCL Great Ormond Street Institute of Child Health, University College London, UK
2. Department of Paediatrics and Child Health, University of Zimbabwe College of Health Sciences, Zimbabwe
3. Specialist Children's and Young People's Services, East London NHS Foundation Trust, London, UK

*These authors contributed equally as first authors.

†These authors contributed equally as last authors.

‡Corresponding author.

Correspondence to:

Dr Felicity Fitzgerald

Infection, Immunity and Inflammation Programme

UCL Great Ormond Street Institute of Child Health

30 Guilford Street

London, WC1N 1EH

United Kingdom

felicity.fitzgerald@ucl.ac.uk

Abstract word count: 258

Main body word count: 1,810

Keywords: neonatal sepsis, clinical prediction models, decision support techniques, diagnosis, scoping review

ABSTRACT

Introduction: Neonatal sepsis is responsible for significant morbidity and mortality worldwide. Diagnosis is often difficult due to non-specific clinical features and unavailability of laboratory tests in many low and middle-income countries. Clinical prediction models have the potential to improve diagnostic accuracy and rationalise antibiotic usage in neonatal units, which may result in reduced antimicrobial resistance and improved neonatal outcomes. In this paper, we outline our scoping review protocol to map the literature concerning clinical prediction models to diagnose neonatal sepsis. We aim to provide an overview of existing models and evidence underlying their use and compare prediction models between high-income and low and middle-income countries.

Methods and analysis: The protocol was developed with reference to recommendations by the Joanna Briggs Institute. Searches will include six electronic databases (Ovid MEDLINE, Ovid Embase, Scopus, Web of Science, Global Index Medicus, and the Cochrane Library) supplemented by hand searching of reference lists and citation analysis on included studies. No time period restrictions will be applied but only studies published in English or Spanish will be included. Screening and data extraction will be performed independently by two reviewers, with a third reviewer used to resolve conflicts. The results will be reported by narrative synthesis in line with the Preferred Reporting Items for Systematic reviews and Meta-Analyses extension for Scoping Reviews (PRISMA-ScR) guidelines.

Ethics and dissemination: The nature of the scoping review methodology means that this study does not require ethical approval. Results will be disseminated through a peer-reviewed publication and conference presentations, as well as through engagement with peers and relevant stakeholders.

ARTICLE SUMMARY

Strengths and limitations of this study

- There have been few recent attempts to scope literature concerning clinical prediction models to diagnose neonatal sepsis across high-income and low and middle-income countries.
- The protocol was developed with reference to recommendations by the Joanna Briggs Institute and the review will be reported in line with the PRISMA-ScR guidelines.
- The search strategy includes six electronic databases, hand searching of reference lists and citation analysis on included studies.
- A limitation of the review is that we will only include non-grey literature published in English or Spanish and it is possible that studies relevant to non-English or non-Spanish speaking settings will not be included.

INTRODUCTION

Despite significant progress in global child health over the past two decades, there were 2.5 million neonatal deaths in 2018 with a global neonatal mortality rate of 18 deaths per 1,000 live births.[1] The vast majority of these deaths occur in low and middle-income countries and are most commonly due to prematurity (35%), intrapartum-related complications (24%) and neonatal sepsis (15%).[1] Neonatal sepsis has an estimated global incidence of 2,202 per 100,000 live births and a global case fatality rate of between 11-19%.[2] Moreover, it is a significant source of morbidity for survivors: complications including neurodevelopmental disorders, cerebral palsy and visual or hearing impairment may persist beyond the neonatal period.[3] Therefore, addressing neonatal sepsis as a preventable and treatable cause of neonatal morbidity and mortality is a global priority.

Neonatal sepsis is a clinical syndrome that results from systemic infection in the first month of life.[4] It is typically classified as early-onset sepsis (EOS, onset within the first 48-72 hours of life) or late-onset sepsis (LOS, onset after the first 48-72 hours of life) to reflect the differing microbiology of these two disease patterns.[5] EOS results from vertically-transmitted infection with pathogens obtained from the maternal genital tract shortly before or during birth.[6] Group B streptococcus (GBS) and *Escherichia coli* account for the majority of cases of EOS in high income settings, and risk factors for these infections include prematurity, low birth weight, prolonged rupture of membranes, maternal fever during labour and maternal rectovaginal colonisation with GBS.[6] In comparison, LOS occurs due to pathogens acquired through interaction with the home or hospital environment.[7] Coagulase-negative staphylococci (CONS) are the commonest organisms of LOS and other major pathogens include *Staphylococcus aureus*, *Escherichia coli*, *Klebsiella* species, *Enterobacter* species, *Pseudomonas* species, and fungal infection with *Candida* species.[7] It should be noted, however, that the exact microbiology of neonatal sepsis differs greatly across geographical regions and is liable to change over time.[8] Furthermore, the microbiology is difficult to determine in settings with limited or no access to reliable culture methods. There is increasing recognition that classification of neonatal sepsis as EOS or LOS is misplaced in low and middle-income countries (LMICs). In these settings, babies are exposed from birth to organisms typically associated with LOS due to poor infection, prevention and control practices such as hand hygiene, aseptic delivery and limited availability of GBS screening services in pregnancy.[9] In a systematic review of data from sub-Saharan Africa, *Staphylococcus aureus* (25%) and *Klebsiella* species (21%) were the most common causative organisms of neonatal sepsis.[10] Thus, in LMICs, it may be sensible to label all infections in facility-born neonates as hospital acquired, even if the infection presents within the first few days of life.[9]

Diagnosis of neonatal sepsis is hindered by non-specific clinical features such as temperature instability, lethargy, poor feeding and respiratory distress, which often overlap with non-infectious diseases. The current gold standard method for diagnosing neonatal sepsis is identification of a pathogenic organism from a normally sterile site (e.g. blood or cerebrospinal fluid).[5] However, *clinical sepsis* (where the infant shows clinical features of sepsis despite negative blood cultures) is a recognised entity and may be more common than blood-culture proven sepsis, especially in the context of previous antibiotic exposure in the baby or mother.[11] When deciding to treat suspected cases of neonatal sepsis, there is a fine balance between failing to treat a serious infection and unnecessary use of antibiotics. Antimicrobial resistance is a growing global concern, with one estimate suggesting that 31% of annual sepsis-related neonatal deaths globally could be attributable to

1
2
3 antimicrobial resistance.[12] Furthermore, some reports have suggested that prolonged exposure to
4 antibiotics are associated with negative neonatal outcomes such as death and necrotising
5 enterocolitis.[13] Therefore, accurately identifying infants with neonatal sepsis is vital to guide optimal
6 use of antibiotics, reduce antimicrobial resistance and improve neonatal outcomes.
7
8

9 **Study rationale**

10
11
12 Clinical prediction models are tools that combine multiple characteristics (or predictors) to estimate
13 the probability of a diagnosis or prognostic outcome and they have gained increasing research
14 attention in recent years.[14] Multiple prediction models exist to estimate the risk of neonatal sepsis
15 based on a wide range of clinical features, risk factors and/or laboratory tests, for example the Kaiser
16 Permanente neonatal sepsis risk calculator for EOS.[15] Clinical prediction models for neonatal sepsis
17 have the potential to improve diagnostic accuracy and rationalise antibiotic usage in neonatal units.
18 Models that do not include laboratory results as predictors are of particular importance in LMICs
19 where basic laboratory tests are often unavailable and the initial care and clinical management of
20 newborn infants may fall to lower cadre healthcare workers in remote settings with limited senior
21 support. Some models used in LMICs have high sensitivity but low specificity for neonatal sepsis and
22 result in overuse of antibiotics.[16]
23
24
25
26

27
28 A search to identify existing scoping reviews or systemic reviews of clinical prediction models to
29 diagnose neonatal sepsis yielded three potentially relevant studies. Two reviews examined clinical
30 prediction models for severe infections in children, however both excluded those targeting
31 neonates.[17, 18] One review examined clinical prediction models for healthcare-associated
32 bloodstream infections in neonates, but they excluded models developed for EOS and the searches
33 are now relatively outdated in this rapidly evolving field.[19] Therefore, the present review will
34 provide an important summary of existing clinical prediction models to diagnose neonatal sepsis to
35 form a basis for future primary research or systematic reviews.
36
37
38

39 **Study objectives**

40
41 The aim of this scoping review is to map the literature concerning clinical prediction models to
42 diagnose neonatal sepsis in high-income countries (HICs) and LMICs.
43
44

45 The specific objectives are:

- 46 • To provide an overview of existing clinical prediction models to diagnose neonatal sepsis.
- 47 • To determine the evidence underlying the use of clinical prediction models to diagnose
48 neonatal sepsis.
- 49 • To compare clinical prediction models to diagnose neonatal sepsis between HICs and LMICs.
- 50 • To identify unanswered research questions surrounding clinical prediction models to diagnose
51 neonatal sepsis, which may guide future primary research or systematic reviews.
52
53
54
55
56
57
58
59
60

METHODS AND ANALYSIS

The methods for this review were developed with reference to the scoping review guidelines provided by the Joanna Briggs Institute.[20] The major components of the review process are detailed in turn below.

Research question

Our review will be guided by the following specific research questions (Table 1).

Table 1. Research questions

1. What clinical prediction models exist to diagnose neonatal sepsis?	
2. What predictors are used in these models?	<ul style="list-style-type: none"> • Symptoms and signs • Risk factors • Laboratory tests
3. What is the evidence underlying the use of these models?	<ul style="list-style-type: none"> • Diagnostic accuracy • Success of implementation • Clinical efficacy
4. How do these models differ between HICs and LMICs?	<ul style="list-style-type: none"> • Number that exist • Predictors used • Evidence supporting use
5. What questions remain unanswered regarding clinical prediction models to diagnose neonatal sepsis?	

Inclusion criteria

The inclusion criteria (Table 2) were formulated according to the 'Population-Concept-Context (PCC)' framework recommended by the Joanna Briggs Institute.[20] As a scoping review is an iterative process, these may be amended as the review progresses and the extent of the literature becomes apparent.

Table 2. Inclusion criteria

Population	<ul style="list-style-type: none"> Human neonates (aged <28 days of life or hospitalised to a neonatal unit) being evaluated for neonatal sepsis (as defined by the individual studies). Studies examining a range of patient ages will be included, providing sufficient data are available to examine findings for neonates in isolation.
Concept	<ul style="list-style-type: none"> Studies that develop, validate or assess the impact of a clinical prediction model to diagnose neonatal sepsis. Studies that report any of: <ul style="list-style-type: none"> modelling methods (including participants, predictors, outcomes and type of model); model performance (including sensitivity and specificity); or success of implementation (including acceptability and any changes to practice or outcomes). Only internally and/or externally validated models will be included. Studies evaluating prognostic models (e.g. to predict neonatal sepsis-related mortality or morbidity) will be excluded.
Context	<ul style="list-style-type: none"> Studies from any country. Studies from any healthcare setting (including neonatal unit, emergency department, outpatient or community setting).
Types of studies	<ul style="list-style-type: none"> Randomised and quasi-randomised controlled trials, cohort studies, cross-sectional studies, case-control studies and guidelines. Letters, comments and conference proceedings will be included if sufficient details are provided. Studies published in English or Spanish. Systematic reviews, meta-analyses and editorials will be excluded, but will be used to identify relevant primary literature.

Search strategy

The following databases will be searched: Ovid MEDLINE and Epub Ahead of Print, In-Process & Other Non-Indexed Citations and Daily; Ovid Embase; Scopus; Web of Science; Global Index Medicus; and the Cochrane Library. Search terms were constructed to capture variations of “neonate”, “sepsis” and “prediction model” by examining the common text words and index terms of known relevant literature. These keywords were further expanded by including relevant potential synonyms. The search strategy for Ovid MEDLINE is detailed in Table 3 and a complete list of search strategies for each database can be found in the supplementary appendix. It is anticipated that additional keywords and index terms may be identified as the review progresses, and these will be incorporated into the search strategy and the searches will be rerun as applicable. To identify additional studies not found through the primary database searches, citation analysis will be performed on included studies using the citation analysis function of Scopus, Web of Science and Google Scholar. Furthermore, the

reference list of included studies will be hand searched. No time period or language restrictions will be applied to the search strategy, but studies will be manually limited to the English or Spanish language at the study selection stage. Searches will be updated prior to publication of our findings to ensure no recent studies are missed.

1	exp Infant, Newborn/
2	(neonat* or newborn* or new born* or baby or babies or premature or preterm or infant* or low birth weight or LBW or VLBW or ELBW or NICU*).ti,ab,kw.
3	1 or 2
4	exp Sepsis/
5	(sepsis or septic* or bacter?emia).ti,ab,kw.
6	4 or 5
7	Decision Support Techniques/ or Neonatal Screening/
8	((predict* or diagnos* or screen* or identif* or manag*) adj5 (model* or rule* or scor* or tool* or algorithm* or decision tree* or pathway* or calculator*)).ti,ab,kw.
9	7 or 8
10	3 and 6 and 9

Evidence selection

All identified records will be imported into EndNote X9 (Clarivate Analytics, 2018) for bibliographic management and deduplication. First, titles and abstracts will be examined against the inclusion criteria (Table 2) to determine whether the study is potentially eligible for inclusion. Next, full texts of potentially eligible studies will be obtained and examined to confirm their eligibility. Relevant authors will be contacted to request full texts, if required. Record screening will be performed independently by two reviewers using the Rayyan web and mobile application.[21] Studies in Spanish will be translated to English and then considered for inclusion. Conflicts will be resolved by a third reviewer and discussion amongst the review team. The first database searches were performed in December 2019 (identifying 2,776 records after deduplication) and title and abstract screening is currently ongoing.

Data extraction

Data extraction will be performed independently by two reviewers. A draft data extraction form has been designed for this review and is shown in the supplementary appendix. This form was adapted from a template provided by the Joanna Briggs Institute[20] and will be further refined as the review progresses. Data to be extracted are based on the Transparent Reporting of a multivariable prediction model for Individual Prognosis or Diagnosis (TRIPOD) statement[22] and include study author(s), year of publication and name of the prediction model described; sources of data, number and characteristics of study participants; type of model, predictors used and defined outcome; and model performance or other evidence regarding the use of the model in clinical practice.

Analysis of the evidence and presentation of the results

The results of this review will be reported by narrative synthesis in line with the recommendations set out in the Preferred Reporting Items for Systematic reviews and Meta-Analyses extension for Scoping Reviews (PRISMA-ScR).[23] The characteristics of several subgroups of clinical prediction models will be compared, including:

- Those that were developed and validated for use in HICs versus LMICs, as defined by the World Bank classification.[24]
- Those for diagnosing specific subgroups of neonatal sepsis (e.g. EOS versus LOS).
- Those based solely on clinical predictors versus those that require laboratory tests.

Data for quantitative outcomes such as model performance or measures of changes to clinical outcomes will not be pooled in a meta-analysis but, rather, general trends will be discussed. Furthermore, explicit risk of bias assessment will not be performed, as our aim is to report the extent of the current literature. It is hoped that this review can then act as a basis to determine important research questions for future primary research and systematic reviews or meta-analyses.

ETHICS AND DISSEMINATION

Since the scoping review methodology involves reviewing and collecting data from publicly available sources, this study does not require ethical approval. The results of this review will be disseminated through a peer-reviewed publication and/or conference presentation. Furthermore, we will engage with the stakeholders of our local and international projects to widen the dissemination of our findings. By identifying gaps in the literature, we hope that this review can form a basis for future primary research and systematic reviews or meta-analyses.

REFERENCES

1. United Nations Inter-agency Group for Child Mortality Estimation. Levels & Trends in Child Mortality: Report 2019. New York: United Nations Children's Fund; 2019.
2. Fleischmann-Struzek, C, Goldfarb, DM, Schlattmann, P, et al. The global burden of paediatric and neonatal sepsis: a systematic review. *Lancet Respir Med*. 2018;6(3):223-30.
3. Seale, AC, Blencowe, H, Zaidi, A, et al. Neonatal severe bacterial infection impairment estimates in South Asia, sub-Saharan Africa, and Latin America for 2010. *Pediatr Res*. 2013;74(1):73-85.
4. Nizet, V, Klein, JO. Bacterial sepsis and meningitis. In: Wilson, CB, Nizet, V, Maldonado, YA, et al., eds. Remington and Klein's infectious diseases of the fetus and newborn infant. 8th ed. Philadelphia: Elsevier Saunders; 2016. p. 217-71.
5. Shane, AL, Sanchez, PJ, Stoll, BJ. Neonatal sepsis. *Lancet*. 2017;390(10104):1770-80.
6. Simonsen, KA, Anderson-Berry, AL, Delair, SF, et al. Early-Onset Neonatal Sepsis. *Clin Microbiol Rev*. 2014;27(1):21-47.
7. Dong, Y, Speer, CP. Late-onset neonatal sepsis: recent developments. *Arch Dis Child Fetal Neonatal Ed*. 2015;100(3):F257-63.
8. Zaidi, AK, Darmstadt, GL, Stoll, BJ. Neonatal infections: a global perspective. In: Wilson, CB, Nizet, V, Maldonado, YA, et al., eds. Remington and Klein's infectious diseases of the fetus and newborn infant. 8th ed. Philadelphia: Elsevier Saunders; 2016. p. 24-53.
9. Zaidi, AK, Huskins, WC, Thaver, D, et al. Hospital-acquired neonatal infections in developing countries. *Lancet*. 2005;365(9465):1175-88.
10. Okomo, U, Akpalu, ENK, Le Doare, K, et al. Aetiology of invasive bacterial infection and antimicrobial resistance in neonates in sub-Saharan Africa: a systematic review and meta-analysis in line with the STROBE-NI reporting guidelines. *Lancet Infect Dis*. 2019;19(11):1219-34.
11. Wynn, JL, Wong, HR, Shanley, TP, et al. Time for a neonatal-specific consensus definition for sepsis. *Pediatr Crit Care Med*. 2014;15(6):523-8.
12. Laxminarayan, R, Matsoso, P, Pant, S, et al. Access to effective antimicrobials: a worldwide challenge. *Lancet*. 2016;387(10014):168-75.
13. Donà, D, Mozzo, E, Mardegan, V, et al. Antibiotics Prescriptions in the Neonatal Intensive Care Unit: How to Overcome Everyday Challenges. *Amer J Perinatol*. 2017;34(12):1169-77.
14. Steyerberg, EW. Clinical Prediction Models. 1st ed. New York: Springer; 2009.
15. Kuzniewicz, MW, Walsh, EM, Li, S, et al. Development and Implementation of an Early-Onset Sepsis Calculator to Guide Antibiotic Management in Late Preterm and Term Neonates. *Jt Comm J Qual Patient Saf*. 2016;42(5):232-9.
16. Chimhini, G, Chimhuya, S, Madzudzo, L, et al. Auditing use of antibiotics in Zimbabwean neonates. *Infection Prevention in Practice*. 2020;2(2):100046.

- 1
2
3 17. Keitel, K, Kilowoko, M, Kyungu, E, et al. Performance of prediction rules and guidelines in
4 detecting serious bacterial infections among Tanzanian febrile children. *BMC Infect Dis*.
5 2019;19(1):769.
6
7 18. Thompson, M, Van den Bruel, A, Verbakel, J, et al. Systematic review and validation of
8 prediction rules for identifying children with serious infections in emergency departments and
9 urgent-access primary care. *Health Technol Assess*. 2012;16(15):1-100.
10
11 19. Verstraete, EH, Blot, K, Mahieu, L, et al. Prediction models for neonatal health care-
12 associated sepsis: a meta-analysis. *Pediatrics*. 2015;135(4):e1002-14.
13
14 20. Joanna Briggs Institute. Development of a scoping review protocol 2019 [cited 2020 04 Apr].
15 Available from:
16 <https://wiki.joannabriggs.org/display/MANUAL/11.2+Development+of+a+scoping+review+protocol>.
17
18 21. Ouzzani, M, Hammady, H, Fedorowicz, Z, et al. Rayyan-a web and mobile app for systematic
19 reviews. *Syst Rev*. 2016;5(1):210.
20
21 22. Moons, KG, Altman, DG, Reitsma, JB, et al. Transparent Reporting of a multivariable
22 prediction model for Individual Prognosis or Diagnosis (TRIPOD): explanation and elaboration. *Ann*
23 *Intern Med*. 2015;162(1):W1-73.
24
25 23. Tricco, AC, Lillie, E, Zarin, W, et al. PRISMA Extension for Scoping Reviews (PRISMA-ScR):
26 Checklist and Explanation. *Ann Intern Med*. 2018;169(7):467-73.
27
28 24. The World Bank. World Bank Country and Lending Groups 2019 [cited 2020 04 Apr].
29 Available from: <https://datahelpdesk.worldbank.org/knowledgebase/articles/906519>.
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

ACKNOWLEDGEMENTS

We would like to thank Heather Chesters (Deputy Librarian at the UCL Great Ormond Street Institute of Child Health Library) for her advice and guidance when developing the search strategy for this review.

AUTHORS' CONTRIBUTIONS

FF and MH conceived the idea for this review. SRN developed the research question, study methods and drafted the manuscript. FF, MH and MCB supervised the protocol design and continue to supervise the review process. GC also supervised the review process. All authors discussed the protocol design and critically edited and approved the final manuscript.

FUNDING STATEMENT

This research received no specific grant from any funding agency in the public, commercial or not-for-profit sectors but was supported by the National Institute for Health Research (NIHR) Great Ormond Street Hospital Biomedical Research Centre. FF is supported by the Academy of Medical Sciences, the funders of the Starter Grant for Clinical Lecturers scheme and the NIHR Great Ormond Street Hospital Biomedical Research Centre. The views expressed are those of the authors and not necessarily those of the National Health Service (NHS), the NIHR or the UK Department of Health.

COMPETING INTERESTS STATEMENT

The authors declare that they have no competing interests.

DATA AVAILABILITY STATEMENT

Data sharing not applicable for this study design.

Supplementary appendix

CONTENTS

1. Search strategies for each database
2. Draft data extraction form

1. SEARCH STRATEGIES FOR EACH DATABASE

Ovid MEDLINE

1	exp Infant, Newborn/
2	(neonat* or newborn* or new born* or baby or babies or premature or preterm or infant* or low birth weight or LBW or VLBW or ELBW or NICU*).ti,ab,kw.
3	1 or 2
4	exp Sepsis/
5	(sepsis or septic* or bacter?emia).ti,ab,kw.
6	4 or 5
7	Decision Support Techniques/ or Neonatal Screening/
8	((predict* or diagnos* or screen* or identif* or manag*) adj5 (model* or rule* or scor* or tool* or algorithm* or decision tree* or pathway* or calculator*)).ti,ab,kw.
9	7 or 8
10	3 and 6 and 9

Ovid Embase

1	newborn/
2	(neonat* or newborn* or new born* or baby or babies or premature or preterm or infant* or low birth weight or LBW or VLBW or ELBW or NICU*).ti,ab,kw.
3	1 or 2
4	exp sepsis/
5	(sepsis or septic* or bacter?emia).ti,ab,kw.
6	4 or 5
7	exp decision support system/ or newborn screening/
8	((predict* or diagnos* or screen* or identif* or manag*) adj5 (model* or rule* or scor* or tool* or algorithm* or decision tree* or pathway* or calculator*)).ti,ab,kw.
9	7 or 8
10	3 and 6 and 9

Scopus

TITLE-ABS-KEY((neonat* OR newborn* OR "new born*" OR baby OR babies OR premature OR preterm OR infant* OR "low birth weight" OR lbw OR vlbw OR elbw OR nicu*) AND (sepsis OR septic* OR bacter?emia) AND ((predict* OR diagnos* OR screen* OR identif* or manag*) W/5 (model* OR rule* OR scor* OR tool* OR algorithm* OR "decision tree*" OR pathway* OR calculator*)))

Web of Science

TS=((neonat* OR newborn* OR "new born*" OR baby OR babies OR premature OR preterm OR infant* OR "low birth weight" OR lbw OR vlbw OR elbw OR nicu*) AND (sepsis OR septic* OR bacter\$emia) AND ((predict* OR diagnos* OR screen* OR identif* or manag*) NEAR/5 (model* OR rule* OR scor* OR tool* OR algorithm* OR "decision tree*" OR pathway* OR calculator*)))

Globus Index Medicus

((mh:("Infant, Newborn")) OR (tw:(neonat* OR newborn* OR "new born*" OR baby OR babies OR premature OR preterm OR infant* OR "low birth weight" OR lbw OR vlbw OR elbw OR nicu*))) AND ((mh:("Sepsis")) OR (tw:(sepsis OR septic* OR bacter*emia))) AND ((mh:("Decision Support Systems, Clinical" OR "Neonatal Screening")) OR (tw:(model* OR rule* OR scor* OR tool* OR algorithm* OR "decision tree*" OR pathway* OR calculator*)))

Cochrane Library

1	MeSH descriptor: [Infant, Newborn] explode all trees
2	(neonat* or newborn* or "new born*" or baby or babies or premature or preterm or infant* or "low birth weight" or LBW or VLBW or ELBW or NICU*):ti,ab,kw
3	#1 or #2
4	MeSH descriptor: [Sepsis] explode all trees
5	(sepsis or septic* or bacter*emia):ti,ab,kw
6	#4 or #5
7	MeSH descriptor: [Decision Support Systems, Clinical] explode all trees
8	MeSH descriptor: [Neonatal Screening] explode all trees
9	((predict* or diagnos* or screen* or identif* or manag* or estimat*) NEAR/5 (model* or rule* or scor* or tool* or algorithm* or "decision tree*" or pathway* or calculator*)):ti,ab,kw
10	#7 or #8 or #9
11	#3 and #6 and #10

2. DRAFT DATA EXTRACTION FORM

Study Details and Characteristics		
Study ID (Author, year)		
Source of data (e.g. RCT)		
Country		
Context (e.g. NICU)		
Participants	Number	
	Characteristics	
Objectives		
Study Results		
Name of prediction model		
Type of model		
Outcome definition		
Predictors used	Symptoms and signs	
	Risk factors	
	Laboratory tests	
Underlying evidence	Model performance (e.g. specificity and sensitivity)	
	Acceptability	
	Mortality	
	Antibiotic prescriptions	
	Other evidence	

BMJ Open

Clinical prediction models to diagnose neonatal sepsis: a scoping review protocol

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2020-039712.R1
Article Type:	Protocol
Date Submitted by the Author:	26-Jun-2020
Complete List of Authors:	Neal, Samuel; University College London, UCL Great Ormond Street Institute of Child Health Musorowegomo, David; University of Zimbabwe College of Health Sciences, Department of Paediatrics and Child Health Gannon, Hannah; University College London, UCL Great Ormond Street Institute of Child Health Cortina Borja, Mario; University College London, UCL Great Ormond Street Institute of Child Health Heys, Michelle; University College London, UCL Great Ormond Street Institute of Child Health; East London NHS Foundation Trust, Specialist Children's and Young People's Services Chimhini, Gwen; University of Zimbabwe College of Health Sciences, Department of Paediatrics and Child Health Fitzgerald, Felicity; University College London, UCL Great Ormond Street Institute of Child Health
Primary Subject Heading:	Paediatrics
Secondary Subject Heading:	Diagnostics, Evidence based practice, Global health, Infectious diseases
Keywords:	NEONATOLOGY, INFECTIOUS DISEASES, STATISTICS & RESEARCH METHODS, Neonatal intensive & critical care < INTENSIVE & CRITICAL CARE, PAEDIATRICS

SCHOLARONE™
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

Clinical prediction models to diagnose neonatal sepsis: a scoping review protocol

Neal SR^{1*}, Musorowegomo D^{2*}, Gannon H¹, Cortina-Borja M¹, Heys M^{1,3}, Chimhini G^{2†}, Fitzgerald F^{1‡}

1. UCL Great Ormond Street Institute of Child Health, University College London, UK
2. Department of Paediatrics and Child Health, University of Zimbabwe College of Health Sciences, Zimbabwe
3. Specialist Children's and Young People's Services, East London NHS Foundation Trust, London, UK

*These authors contributed equally as first authors.

†These authors contributed equally as last authors.

‡Corresponding author.

Correspondence to:

Dr Felicity Fitzgerald

Infection, Immunity and Inflammation Programme

UCL Great Ormond Street Institute of Child Health

30 Guilford Street

London, WC1N 1EH

United Kingdom

felicity.fitzgerald@ucl.ac.uk

Abstract word count: 258

Main body word count: 1,859

Keywords: neonatal sepsis, clinical prediction models, decision support techniques, diagnosis, scoping review

ABSTRACT

Introduction: Neonatal sepsis is responsible for significant morbidity and mortality worldwide. Diagnosis is often difficult due to non-specific clinical features and unavailability of laboratory tests in many low and middle-income countries. Clinical prediction models have the potential to improve diagnostic accuracy and rationalise antibiotic usage in neonatal units, which may result in reduced antimicrobial resistance and improved neonatal outcomes. In this paper, we outline our scoping review protocol to map the literature concerning clinical prediction models to diagnose neonatal sepsis. We aim to provide an overview of existing models and evidence underlying their use and compare prediction models between high-income and low and middle-income countries.

Methods and analysis: The protocol was developed with reference to recommendations by the Joanna Briggs Institute. Searches will include six electronic databases (Ovid MEDLINE, Ovid Embase, Scopus, Web of Science, Global Index Medicus, and the Cochrane Library) supplemented by hand searching of reference lists and citation analysis on included studies. No time period restrictions will be applied but only studies published in English or Spanish will be included. Screening and data extraction will be performed independently by two reviewers, with a third reviewer used to resolve conflicts. The results will be reported by narrative synthesis in line with the Preferred Reporting Items for Systematic reviews and Meta-Analyses extension for Scoping Reviews (PRISMA-ScR) guidelines.

Ethics and dissemination: The nature of the scoping review methodology means that this study does not require ethical approval. Results will be disseminated through a peer-reviewed publication and conference presentations, as well as through engagement with peers and relevant stakeholders.

ARTICLE SUMMARY

Strengths and limitations of this study

- There have been few recent attempts to scope literature concerning clinical prediction models to diagnose neonatal sepsis across high-income and low and middle-income countries.
- The protocol was developed with reference to recommendations by the Joanna Briggs Institute and the review will be reported in line with the PRISMA-ScR guidelines.
- The search strategy includes six electronic databases, hand searching of reference lists and citation analysis on included studies.
- A limitation of the review is that we will only include non-grey literature published in English or Spanish and it is possible that studies relevant to non-English or non-Spanish speaking settings will not be included.

INTRODUCTION

Despite significant progress in global child health over the past two decades, there were 2.5 million neonatal deaths in 2018 with a global neonatal mortality rate of 18 deaths per 1,000 live births.[1] The vast majority of these deaths occur in low and middle-income countries and are most commonly due to prematurity (35%), intrapartum-related complications (24%) and neonatal sepsis (15%).[1] Neonatal sepsis has an estimated global incidence of 2,202 per 100,000 live births and a global case fatality rate of between 11-19%.[2] Moreover, it is a significant source of morbidity for survivors: complications including neurodevelopmental disorders, cerebral palsy and visual or hearing impairment may persist beyond the neonatal period.[3] Therefore, addressing neonatal sepsis as a preventable and treatable cause of neonatal morbidity and mortality is a global priority.

Neonatal sepsis is a clinical syndrome that results from systemic infection in the first month of life.[4] It is typically classified as early-onset sepsis (EOS, onset within the first 48-72 hours of life) or late-onset sepsis (LOS, onset after the first 48-72 hours of life) to reflect the differing microbiology of these two disease patterns.[5] EOS results from vertically-transmitted infection with pathogens obtained from the maternal genital tract shortly before or during birth.[6] Group B streptococcus (GBS) and *Escherichia coli* account for the majority of cases of EOS in high income settings, and risk factors for these infections include prematurity, low birth weight, prolonged rupture of membranes, maternal fever during labour and maternal rectovaginal colonisation with GBS.[6] In comparison, LOS occurs due to pathogens acquired through interaction with the home or hospital environment.[7] Coagulase-negative staphylococci (CONS) are the commonest organisms of LOS and other major pathogens include *Staphylococcus aureus*, *Escherichia coli*, *Klebsiella* species, *Enterobacter* species, *Pseudomonas* species, and fungal infection with *Candida* species.[7] It should be noted, however, that the exact microbiology of neonatal sepsis differs greatly across geographical regions and is liable to change over time.[8] Furthermore, the microbiology is difficult to determine in settings with limited or no access to reliable culture methods. There is increasing recognition that classification of neonatal sepsis as EOS or LOS is misplaced in low and middle-income countries (LMICs). In these settings, babies are exposed from birth to organisms typically associated with LOS due to poor infection prevention and control practices such as hand hygiene, aseptic delivery and limited availability of GBS screening services in pregnancy.[9] In a systematic review of data from sub-Saharan Africa, *Staphylococcus aureus* (25%) and *Klebsiella* species (21%) were the most common causative organisms of neonatal sepsis.[10] Thus, in LMICs, it may be sensible to label all infections in facility-born neonates as hospital acquired, even if the infection presents within the first few days of life.[9]

Diagnosis of neonatal sepsis is hindered by non-specific clinical features such as temperature instability, lethargy, poor feeding and respiratory distress, which often overlap with non-infectious diseases. The current gold standard method for diagnosing neonatal sepsis is identification of a pathogenic organism from a normally sterile site (e.g. blood or cerebrospinal fluid).[5] However, *clinical sepsis* (where the infant shows clinical features of sepsis despite negative blood cultures) is a recognised entity and may be more common than blood-culture proven sepsis, especially in the context of previous antibiotic exposure in the baby or mother.[11] When deciding to treat suspected cases of neonatal sepsis, there is a fine balance between failing to treat a serious infection and unnecessary use of antibiotics. Antimicrobial resistance is a growing global concern, with one estimate suggesting that 31% of annual sepsis-related neonatal deaths globally could be attributable to

1
2
3 antimicrobial resistance.[12] Furthermore, some reports have suggested that prolonged exposure to
4 antibiotics is associated with negative neonatal outcomes such as death and necrotising
5 enterocolitis.[13] Therefore, accurately identifying infants with neonatal sepsis is vital to guide optimal
6 use of antibiotics, reduce antimicrobial resistance and improve neonatal outcomes.
7
8

9 **Study rationale**

10
11
12 Clinical prediction models are tools that combine multiple characteristics (or predictors) to estimate
13 the probability of a diagnosis or prognostic outcome and they have gained increasing research
14 attention in recent years.[14] Multiple prediction models exist to estimate the risk of neonatal sepsis
15 based on a wide range of clinical features, risk factors and/or laboratory tests, for example the Kaiser
16 Permanente neonatal sepsis risk calculator for EOS.[15] Clinical prediction models for neonatal sepsis
17 have the potential to improve diagnostic accuracy and rationalise antibiotic usage in neonatal units.
18 Models that do not include laboratory results as predictors are of particular importance in LMICs
19 where basic laboratory tests are often unavailable and the initial care and clinical management of
20 newborn infants may fall to lower cadre healthcare workers in remote settings with limited senior
21 support. Some models used in LMICs have high sensitivity but low specificity for neonatal sepsis and
22 result in overuse of antibiotics.[16]
23
24
25
26

27
28 A search to identify existing scoping reviews or systemic reviews of clinical prediction models to
29 diagnose neonatal sepsis yielded three potentially relevant studies. Two reviews examined clinical
30 prediction models for severe infections in children, however both excluded those targeting
31 neonates.[17, 18] One review examined clinical prediction models for healthcare-associated
32 bloodstream infections in neonates, but they excluded models developed for EOS and the searches
33 are now relatively outdated in this rapidly evolving field.[19] Therefore, the present review will
34 provide an important summary of existing clinical prediction models to diagnose neonatal sepsis to
35 form a basis for future primary research or systematic reviews.
36
37
38

39 **Study objectives**

40
41 The aim of this scoping review is to map the literature concerning clinical prediction models to
42 diagnose neonatal sepsis in high-income countries (HICs) and LMICs.
43
44

45 The specific objectives are:

- 46 • To provide an overview of existing clinical prediction models to diagnose neonatal sepsis.
- 47 • To determine the evidence underlying the use of clinical prediction models to diagnose
48 neonatal sepsis.
- 49 • To compare clinical prediction models to diagnose neonatal sepsis between HICs and LMICs.
- 50 • To identify unanswered research questions surrounding clinical prediction models to diagnose
51 neonatal sepsis, which may guide future primary research or systematic reviews.
52
53
54
55
56
57
58
59
60

METHODS AND ANALYSIS

The methods for this review were developed with reference to the scoping review guidelines provided by the Joanna Briggs Institute.[20] The major components of the review process are detailed in turn below.

Research question

Our review will be guided by the following specific research questions (Table 1).

Table 1. Research questions

1. What clinical prediction models exist to diagnose neonatal sepsis?	
2. What modelling methods are used to derive these models?	
3. What predictors are used in these models?	<ul style="list-style-type: none"> • Symptoms and signs • Risk factors • Laboratory tests
4. What is the evidence underlying the use of these models?	<ul style="list-style-type: none"> • Type of studies • Diagnostic accuracy • Success of implementation • Clinical efficacy
5. How do these models differ between HICs and LMICs?	<ul style="list-style-type: none"> • Number that exist • Predictors used • Evidence supporting use
6. What questions remain unanswered regarding clinical prediction models to diagnose neonatal sepsis?	

Inclusion criteria

The inclusion criteria (Table 2) were formulated according to the 'Population-Concept-Context (PCC)' framework recommended by the Joanna Briggs Institute.[20] As a scoping review is an iterative process, these may be amended as the review progresses and the extent of the literature becomes apparent.

Table 2. Inclusion criteria

Population	<ul style="list-style-type: none"> Human neonates (aged <28 days of life or hospitalised to a neonatal unit) being evaluated for neonatal sepsis (as defined by the individual studies). Studies examining a range of patient ages will be included, providing sufficient data are available to examine findings for neonates in isolation.
Concept	<ul style="list-style-type: none"> Studies that develop, validate or assess the impact of a clinical prediction model to diagnose neonatal sepsis. Studies that report any of: <ul style="list-style-type: none"> modelling methods (including participants, predictors, outcomes and type of model); model performance (including sensitivity and specificity); or success of implementation (including acceptability and any changes to practice or outcomes). Only internally and/or externally validated models will be included. Management algorithms, decision rules or prediction models based on expert opinion will not be included, unless validated in a subsequent study. Studies evaluating prognostic models (e.g. to predict neonatal sepsis-related mortality or morbidity) will be excluded.
Context	<ul style="list-style-type: none"> Studies from any country. Studies from any healthcare setting (including neonatal unit, emergency department, outpatient or community setting).
Types of studies	<ul style="list-style-type: none"> Randomised and quasi-randomised controlled trials, cohort studies, cross-sectional studies, case-control studies and guidelines. Letters, comments and conference proceedings will be included if sufficient details are provided. Studies published in English or Spanish. Systematic reviews, meta-analyses and editorials will be excluded, but will be used to identify relevant primary literature.

Search strategy

The following databases will be searched: Ovid MEDLINE and Epub Ahead of Print, In-Process & Other Non-Indexed Citations and Daily; Ovid Embase; Scopus; Web of Science; Global Index Medicus; and the Cochrane Library. Search terms were constructed to capture variations of “neonate”, “sepsis” and “prediction model” by examining the common text words and index terms of known relevant literature. These keywords were further expanded by including relevant potential synonyms. The search strategy for Ovid MEDLINE is detailed in Table 3 and a complete list of search strategies for each database can be found in the supplementary appendix. It is anticipated that additional keywords and index terms may be identified as the review progresses, and these will be incorporated into the

search strategy and the searches will be rerun as applicable. To identify additional studies not found through the primary database searches, citation analysis will be performed on included studies using the citation analysis function of Scopus, Web of Science and Google Scholar. Furthermore, the reference list of included studies will be hand searched. No time period or language restrictions will be applied to the search strategy, but studies will be manually limited to the English or Spanish language at the study selection stage to reflect the languages spoken by the review team. Searches will be updated prior to publication of our findings to ensure no recent studies are missed.

Table 3. Search strategy for Ovid MEDLINE

1	exp Infant, Newborn/
2	(neonat* or newborn* or new born* or baby or babies or premature or preterm or infant* or low birth weight or LBW or VLBW or ELBW or NICU*).ti,ab,kw.
3	1 or 2
4	exp Sepsis/
5	(sepsis or septic* or bacter?emia).ti,ab,kw.
6	4 or 5
7	Decision Support Techniques/ or Neonatal Screening/
8	((predict* or diagnos* or screen* or identif* or manag*) adj5 (model* or rule* or scor* or tool* or algorithm* or decision tree* or pathway* or calculator*)).ti,ab,kw.
9	7 or 8
10	3 and 6 and 9

Evidence selection

All identified records will be imported into EndNote X9 (Clarivate Analytics, 2018) for bibliographic management and deduplication. First, titles and abstracts will be examined against the inclusion criteria (Table 2) to determine whether the study is potentially eligible for inclusion. Next, full texts of potentially eligible studies will be obtained and examined to confirm their eligibility. Relevant authors will be contacted to request full texts, if required. Record screening will be performed independently by two reviewers using the Rayyan web and mobile application.[21] Studies in Spanish will be translated to English by MCB and then considered for inclusion. Conflicts will be resolved by a third reviewer and discussion amongst the review team. The first database searches were performed in December 2019 (identifying 2,776 records after deduplication) and title and abstract screening is currently ongoing.

Data extraction

Data extraction will be performed independently by two reviewers. A draft data extraction form has been designed for this review and is shown in the supplementary appendix. This form was adapted from a template provided by the Joanna Briggs Institute[20] and will be further refined as the review progresses. Data to be extracted are based on the Transparent Reporting of a multivariable prediction model for Individual Prognosis or Diagnosis (TRIPOD) statement[22] and include study author(s), year of publication and name of the prediction model described; sources of data, number and

1
2
3 characteristics of study participants; type of model, predictors used and defined outcome; and model
4 performance or other evidence regarding the use of the model in clinical practice.
5
6

7 **Analysis of the evidence and presentation of the results**

8

9 The results of this review will be reported by narrative synthesis in line with the recommendations set
10 out in the Preferred Reporting Items for Systematic reviews and Meta-Analyses extension for Scoping
11 Reviews (PRISMA-ScR).[23] The characteristics of several subgroups of clinical prediction models will
12 be compared, including:
13

- 14 • Those that were developed and validated for use in HICs versus LMICs, as defined by the World
15 Bank classification.[24]
- 16 • Those for diagnosing specific subgroups of neonatal sepsis (e.g. EOS versus LOS).
- 17 • Those based solely on clinical predictors versus those that require laboratory tests.
- 18 • Those that specifically consider the management of neonates born to mothers with
19 chorioamnionitis.
- 20 • Those using different outcome definitions for neonatal sepsis (such as those defining sepsis
21 as a positive blood culture versus those that also include 'clinical sepsis').
22
23
24
25

26 Data for quantitative outcomes such as model performance or measures of changes to clinical
27 outcomes will not be pooled in a meta-analysis but, rather, general trends will be discussed.
28 Furthermore, explicit risk of bias assessment will not be performed, as our aim is to report the extent
29 of the current literature. It is hoped that this review can then act as a basis to determine important
30 research questions for future primary research and systematic reviews or meta-analyses.
31
32

33 **Patient and public involvement**

34

35 This research was done without patient involvement. Patients were not invited to comment on the
36 study design and were not consulted to develop patient relevant outcomes or interpret the results.
37 Patients were not invited to contribute to the writing or editing of this document for readability or
38 accuracy.
39
40
41
42

43 **ETHICS AND DISSEMINATION**

44

45 Since the scoping review methodology involves reviewing and collecting data from publicly available
46 sources, this study does not require ethical approval. The results of this review will be disseminated
47 through a peer-reviewed publication and/or conference presentation. Furthermore, we will engage
48 with the stakeholders of our local and international projects to widen the dissemination of our
49 findings. By identifying gaps in the literature, we hope that this review can form a basis for future
50 primary research and systematic reviews or meta-analyses.
51
52
53
54
55
56
57
58
59
60

REFERENCES

1. United Nations Inter-agency Group for Child Mortality Estimation. Levels & Trends in Child Mortality: Report 2019. New York: United Nations Children's Fund; 2019.
2. Fleischmann-Struzek, C, Goldfarb, DM, Schlattmann, P, et al. The global burden of paediatric and neonatal sepsis: a systematic review. *Lancet Respir Med*. 2018;6(3):223-30.
3. Seale, AC, Blencowe, H, Zaidi, A, et al. Neonatal severe bacterial infection impairment estimates in South Asia, sub-Saharan Africa, and Latin America for 2010. *Pediatr Res*. 2013;74(1):73-85.
4. Nizet, V, Klein, JO. Bacterial sepsis and meningitis. In: Wilson, CB, Nizet, V, Maldonado, YA, et al., eds. Remington and Klein's infectious diseases of the fetus and newborn infant. 8th ed. Philadelphia: Elsevier Saunders; 2016. p. 217-71.
5. Shane, AL, Sanchez, PJ, Stoll, BJ. Neonatal sepsis. *Lancet*. 2017;390(10104):1770-80.
6. Simonsen, KA, Anderson-Berry, AL, Delair, SF, et al. Early-Onset Neonatal Sepsis. *Clin Microbiol Rev*. 2014;27(1):21-47.
7. Dong, Y, Speer, CP. Late-onset neonatal sepsis: recent developments. *Arch Dis Child Fetal Neonatal Ed*. 2015;100(3):F257-63.
8. Zaidi, AK, Darmstadt, GL, Stoll, BJ. Neonatal infections: a global perspective. In: Wilson, CB, Nizet, V, Maldonado, YA, et al., eds. Remington and Klein's infectious diseases of the fetus and newborn infant. 8th ed. Philadelphia: Elsevier Saunders; 2016. p. 24-53.
9. Zaidi, AK, Huskins, WC, Thaver, D, et al. Hospital-acquired neonatal infections in developing countries. *Lancet*. 2005;365(9465):1175-88.
10. Okomo, U, Akpalu, ENK, Le Doare, K, et al. Aetiology of invasive bacterial infection and antimicrobial resistance in neonates in sub-Saharan Africa: a systematic review and meta-analysis in line with the STROBE-NI reporting guidelines. *Lancet Infect Dis*. 2019;19(11):1219-34.
11. Wynn, JL, Wong, HR, Shanley, TP, et al. Time for a neonatal-specific consensus definition for sepsis. *Pediatr Crit Care Med*. 2014;15(6):523-8.
12. Laxminarayan, R, Matsoso, P, Pant, S, et al. Access to effective antimicrobials: a worldwide challenge. *Lancet*. 2016;387(10014):168-75.
13. Donà, D, Mozzo, E, Mardegan, V, et al. Antibiotics Prescriptions in the Neonatal Intensive Care Unit: How to Overcome Everyday Challenges. *Amer J Perinatol*. 2017;34(12):1169-77.
14. Steyerberg, EW. Clinical Prediction Models. 1st ed. New York: Springer; 2009.
15. Kuzniewicz, MW, Walsh, EM, Li, S, et al. Development and Implementation of an Early-Onset Sepsis Calculator to Guide Antibiotic Management in Late Preterm and Term Neonates. *Jt Comm J Qual Patient Saf*. 2016;42(5):232-9.
16. Chimhini, G, Chimhuya, S, Madzudzo, L, et al. Auditing use of antibiotics in Zimbabwean neonates. *Infection Prevention in Practice*. 2020;2(2):100046.

- 1
2
3 17. Keitel, K, Kilowoko, M, Kyungu, E, et al. Performance of prediction rules and guidelines in
4 detecting serious bacterial infections among Tanzanian febrile children. *BMC Infect Dis*.
5 2019;19(1):769.
6
7 18. Thompson, M, Van den Bruel, A, Verbakel, J, et al. Systematic review and validation of
8 prediction rules for identifying children with serious infections in emergency departments and
9 urgent-access primary care. *Health Technol Assess*. 2012;16(15):1-100.
10
11 19. Verstraete, EH, Blot, K, Mahieu, L, et al. Prediction models for neonatal health care-
12 associated sepsis: a meta-analysis. *Pediatrics*. 2015;135(4):e1002-14.
13
14 20. Joanna Briggs Institute. Development of a scoping review protocol 2019 [cited 2020 04 Apr].
15 Available from:
16 <https://wiki.joannabriggs.org/display/MANUAL/11.2+Development+of+a+scoping+review+protocol>.
17
18 21. Ouzzani, M, Hammady, H, Fedorowicz, Z, et al. Rayyan-a web and mobile app for systematic
19 reviews. *Syst Rev*. 2016;5(1):210.
20
21 22. Moons, KG, Altman, DG, Reitsma, JB, et al. Transparent Reporting of a multivariable
22 prediction model for Individual Prognosis or Diagnosis (TRIPOD): explanation and elaboration. *Ann*
23 *Intern Med*. 2015;162(1):W1-73.
24
25 23. Tricco, AC, Lillie, E, Zarin, W, et al. PRISMA Extension for Scoping Reviews (PRISMA-ScR):
26 Checklist and Explanation. *Ann Intern Med*. 2018;169(7):467-73.
27
28 24. The World Bank. World Bank Country and Lending Groups 2019 [cited 2020 04 Apr].
29 Available from: <https://datahelpdesk.worldbank.org/knowledgebase/articles/906519>.
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

ACKNOWLEDGEMENTS

We would like to thank Heather Chesters (Deputy Librarian at the UCL Great Ormond Street Institute of Child Health Library) for her advice and guidance when developing the search strategy for this review.

AUTHORS' CONTRIBUTIONS

FF and MH conceived the idea for this review. SRN developed the research question, study methods and drafted the manuscript. FF, MH, GC and MCB supervised the protocol design and continue to supervise the review process. SRN, DM and HG piloted the protocol and continue to screen records for inclusion. All authors discussed the protocol design and critically edited and approved the final manuscript.

FUNDING STATEMENT

This research received no specific grant from any funding agency in the public, commercial or not-for-profit sectors but was supported by the National Institute for Health Research (NIHR) Great Ormond Street Hospital Biomedical Research Centre. FF is supported by the Academy of Medical Sciences, the funders of the Starter Grant for Clinical Lecturers scheme and the NIHR Great Ormond Street Hospital Biomedical Research Centre. The views expressed are those of the authors and not necessarily those of the National Health Service (NHS), the NIHR or the UK Department of Health.

COMPETING INTERESTS STATEMENT

The authors declare that they have no competing interests.

DATA AVAILABILITY STATEMENT

Data sharing not applicable for this study design.

Supplementary appendix

CONTENTS

1. Search strategies for each database
2. Draft data extraction form

1. SEARCH STRATEGIES FOR EACH DATABASE

Ovid MEDLINE

1	exp Infant, Newborn/
2	(neonat* or newborn* or new born* or baby or babies or premature or preterm or infant* or low birth weight or LBW or VLBW or ELBW or NICU*).ti,ab,kw.
3	1 or 2
4	exp Sepsis/
5	(sepsis or septic* or bacter?emia).ti,ab,kw.
6	4 or 5
7	Decision Support Techniques/ or Neonatal Screening/
8	((predict* or diagnos* or screen* or identif* or manag*) adj5 (model* or rule* or scor* or tool* or algorithm* or decision tree* or pathway* or calculator*)).ti,ab,kw.
9	7 or 8
10	3 and 6 and 9

Ovid Embase

1	newborn/
2	(neonat* or newborn* or new born* or baby or babies or premature or preterm or infant* or low birth weight or LBW or VLBW or ELBW or NICU*).ti,ab,kw.
3	1 or 2
4	exp sepsis/
5	(sepsis or septic* or bacter?emia).ti,ab,kw.
6	4 or 5
7	exp decision support system/ or newborn screening/
8	((predict* or diagnos* or screen* or identif* or manag*) adj5 (model* or rule* or scor* or tool* or algorithm* or decision tree* or pathway* or calculator*)).ti,ab,kw.
9	7 or 8
10	3 and 6 and 9

Scopus

TITLE-ABS-KEY((neonat* OR newborn* OR "new born*" OR baby OR babies OR premature OR preterm OR infant* OR "low birth weight" OR lbw OR vlbw OR elbw OR nicu*) AND (sepsis OR septic* OR bacter?emia) AND ((predict* OR diagnos* OR screen* OR identif* or manag*) W/5 (model* OR rule* OR scor* OR tool* OR algorithm* OR "decision tree*" OR pathway* OR calculator*)))

Web of Science

TS=((neonat* OR newborn* OR "new born*" OR baby OR babies OR premature OR preterm OR infant* OR "low birth weight" OR lbw OR vlbw OR elbw OR nicu*) AND (sepsis OR septic* OR bacter\$emia) AND ((predict* OR diagnos* OR screen* OR identif* or manag*) NEAR/5 (model* OR rule* OR scor* OR tool* OR algorithm* OR "decision tree*" OR pathway* OR calculator*)))

Globus Index Medicus

((mh:("Infant, Newborn")) OR (tw:(neonat* OR newborn* OR "new born*" OR baby OR babies OR premature OR preterm OR infant* OR "low birth weight" OR lbw OR vlbw OR elbw OR nicu*))) AND ((mh:("Sepsis")) OR (tw:(sepsis OR septic* OR bacter*emia))) AND ((mh:("Decision Support Systems, Clinical" OR "Neonatal Screening")) OR (tw:(model* OR rule* OR scor* OR tool* OR algorithm* OR "decision tree*" OR pathway* OR calculator*)))

Cochrane Library

1	MeSH descriptor: [Infant, Newborn] explode all trees
2	(neonat* or newborn* or "new born*" or baby or babies or premature or preterm or infant* or "low birth weight" or LBW or VLBW or ELBW or NICU*):ti,ab,kw
3	#1 or #2
4	MeSH descriptor: [Sepsis] explode all trees
5	(sepsis or septic* or bacter*emia):ti,ab,kw
6	#4 or #5
7	MeSH descriptor: [Decision Support Systems, Clinical] explode all trees
8	MeSH descriptor: [Neonatal Screening] explode all trees
9	((predict* or diagnos* or screen* or identif* or manag* or estimat*) NEAR/5 (model* or rule* or scor* or tool* or algorithm* or "decision tree*" or pathway* or calculator*)):ti,ab,kw
10	#7 or #8 or #9
11	#3 and #6 and #10

2. DRAFT DATA EXTRACTION FORM

Study Details and Characteristics		
Study ID (Author, year)		
Source of data (e.g. RCT)		
Country		
Context (e.g. NICU)		
Participants	Number	
	Characteristics	
Objectives		
Study Results		
Name of prediction model		
Type of model		
Outcome definition		
Predictors used	Symptoms and signs	
	Risk factors	
	Laboratory tests	
Underlying evidence	Model performance (e.g. specificity and sensitivity)	
	Acceptability	
	Mortality	
	Antibiotic prescriptions	
	Other evidence	